Effects of Conjugated Equine Estrogen on Health-Related Quality of Life in Postmenopausal Women With Hysterectomy
Authors:
- Robert L. BrunnerRBRobert L. Brunner
- Margery GassMGMargery Gass
- Aaron AragakiAAAaron Aragaki
- Jennifer HaysJHJennifer Hays
- Iris GranekIGIris Granek
- Nancy WoodsNWNancy Woods
- Ellen MasonEMEllen Mason
- Robert BrzyskiRBRobert Brzyski
- Judith OckeneJOJudith Ockene
- Annlouise AssafAAAnnlouise Assaf
- Andrea LaCroixALAndrea LaCroix
- Karen MatthewsKMKaren Matthews
Open Access
- 26 September 2005
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 165 (17) , 1976-1986
Abstract
Results of recently published large, randomized clinical trials have failed to support protective effects of oral estrogen therapy alone or estrogen plus progestin therapy on cardiovascular disease when administered to postmenopausal women.1-3 Findings of the Women’s Health Initiative (WHI)4 demonstrated that, compared with placebo, women taking conjugated equine estrogens (CEEs) were at increased risk for stroke and deep vein thrombosis and at decreased risk for osteoporotic fractures. The global risk-benefit profile was neutral in the CEE treatment group, and the planned 8.5-year randomized clinical trial (RCT) was stopped after an average of 6.8 years of follow-up (range, 5.7-10.7 years). Although the parallel WHI trial of CEE and medroxyprogesterone acetate (CEE + MPA) and other results showed that active treatment produced relief from vasomotor symptoms, the health-related quality of life (HRQOL) effects were limited to modest changes in physical functioning, sleep disturbance, and bodily pain that were considered too small to be of clinical significance on a population basis.5-7Keywords
This publication has 30 references indexed in Scilit:
- Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomized Controlled TrialACC Current Journal Review, 2004
- Measuring quality of life in chronic illness: The functional assessment of chronic illness therapy measurement systemArchives of Physical Medicine and Rehabilitation, 2002
- Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)—CorrectionJAMA, 2002
- Generic, Disease-Specific and Individualised Approaches to Measuring Health-Related Quality of Life Among People With Heart Disease - A Comparative AnalysisPsychology & Health, 2002
- Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groupsSocial Science & Medicine, 2001
- Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trialObstetrics & Gynecology, 1998
- The impact of hormone replacement therapy on quality of life and willingness to payBJOG: An International Journal of Obstetrics & Gynaecology, 1997
- The problem of quality of lifeQuality of Life Research, 1997
- Assessing the validity of the SF-36 General Health SurveyQuality of Life Research, 1997
- Menopausal women as decision makers in health careExperimental Gerontology, 1994